KCIA
AUPH icon

Kingsbury Capital Investment Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$244K Buy
32,424
+17,758
+121% +$154K 0.37% 55
2022
Q2 		$147K Sell
14,666
-6,472
-31% -$72.3K 0.2% 79
2022
Q1 		$262K Buy
+21,138
New +$327K 0.29% 72

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kingsbury Capital Investment Advisors's AUPH Position: Q3 2022 in Review

Kingsbury Capital Investment Advisors increased its Aurinia Pharmaceuticals (AUPH) stake by 121% in Q3 2022, buying an estimated $154K and bringing the position to 32,424 shares worth $244K. The position accounts for 0.37% of the portfolio, ranked #55.

Kingsbury Capital Investment Advisors first reported a position in AUPH in Q1 2022 and has held it in 3 quarters since. The position peaked at $262K in Q1 2022. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

  • Kingsbury Capital Investment Advisors held 32,424 shares of Aurinia Pharmaceuticals worth $244K as of Q3 2022.
  • Kingsbury Capital Investment Advisors bought 17,758 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $154K.
  • Aurinia Pharmaceuticals made up 0.37% of Kingsbury Capital Investment Advisors's portfolio in Q3 2022, its #55 holding.
  • Kingsbury Capital Investment Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • Kingsbury Capital Investment Advisors's Aurinia Pharmaceuticals position peaked at $262K in Q1 2022.
  • 189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.